# US 2016/0235892 A1 · Decellularized hyaline cartilage powder for tissue scaffolds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0235892 A1
- Document ID: US20160235892A1
- Status: Published application
- Kind: A1
- Application number: 15/024,317
- Filed: 2014-09-25
- Published: 2016-08-18
- Earliest claimed: 2013-09-25
- Assignees: The Children's Mercy Hospital; University of Kansas
- Applicants: The Children's Mercy Hospital; The University of Kansas
- Inventors: Michael Detamore; Amanda Renth; Amanda Sutherland; Emily Beck; Richard Hopkins; Gabriel Converse
- Web page: https://patentgrep.com/patent/US20160235892A1

## CPC

- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A61L 27/20: Polysaccharides
- A61L 27/3612: {Cartilage, synovial fluid}
- A61L 27/3687: {characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents}
- A61L 27/3691: {characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation}
- A61L 27/52: Hydrogels or hydrocolloids
- A61L 2300/606: Coatings
- A61L 2300/622: Microcapsules
- A61L 2430/02: for reconstruction of bones; weight-bearing implants
- A61L 2430/06: for cartilage reconstruction, e.g. meniscus
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention is related to compositions comprising decellularized cartilage tissue powder in the forms of paste, putty, hydrogel, and scaffolds, methods of making compositions, and methods of using these compositions for treating osteochondral defects and full- or partial-thickness cartilage defects.

## Claims

### Claim 1

A composition comprising: decellularized cartilage (DCC) powder, wherein the powder includes particulates ranging in size from about 1 nanometer to about 500 micrometers.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the DCC powder is soluble, has no more than about 20% of dsDNA left and has about 85% or more glycosaminoglycan content retained, in comparison to fresh cartilage tissue.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said DCC powder stimulates bone marrow stem cell responses.

### Claim 4 (depends on 1)

The composition of claim 1, the composition formed as a hyaline cartilage tissue hydrogel, comprising:
the decellularized cartilage (DCC) powder having a majority of the particulates ranging in size between about 1 nanometer and about 500 micrometers, and
at least one hydrogel.

### Claim 5 (depends on 4)

The composition of claim 4, wherein said hydrogel is Methacrylated Hyaluronic Acid (MeHA) and wherein said cartilage tissue hydrogel has a yield stress of at least 100 Pa.

### Claim 6

A hyaline cartilage tissue paste comprising:
10-90% w/v slightly solubilized decellularized cartilage powder; and
10-90% w/v of a hydrogel.

### Claim 7 (depends on 6)

The hyaline cartilage tissue paste of claim 6, wherein said hydrogel is Methacrylated hyaluronic acid (MeHA).

### Claim 8 (depends on 6)

The hyaline cartilage tissue paste of claim 6, further comprising one or more additives selected from the group consisting of carriers, one or more therapeutic agents, one or more biomaterials for tissue engineering scaffolds, and combinations thereof.

### Claim 9 (depends on 1)

The composition of claim 1, comprising:
polymeric microspheres in contact with the decellularized cartilage (DCC) powder, wherein the decellularized cartilage powder includes particulates ranging in size from between about 1 nanometers and about 500 micrometers.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the decellularized cartilage (DCC) powder is coated onto said microspheres.

### Claim 11 (depends on 9)

The composition of claim 9, wherein the decellularized cartilage (DCC) powder is encapsulated in said microspheres.

### Claim 12 (depends on 9)

The composition of claim 9, wherein said composition is in a form of a tissue engineering scaffold.

### Claim 13 (depends on 12)

The composition of claim 12, wherein the tissue engineering scaffold includes the polymer microspheres coated with the decellularized cartilage (DCC) powder having particulates ranging in size from about 1 nanometers to about 500 micrometers.

### Claim 14 (depends on 12)

The composition of claim 12, wherein the tissue engineering scaffold includes the polymer microspheres encapsulated with the decellularized cartilage (DCC) powder having particulates ranging in size from about 1 nanometers to about 500 micrometers.

### Claim 15 (depends on 1)

A method of preparing the composition of claim 1 having the decellularized cartilage (DCC) powder, the method comprising:
a. pulverizing cartilage tissue to form cartilage tissue fragments;
b. decellularizing the cartilage tissue fragments to produce decellularized cartilage (DCC) tissue fragments ranging in size from about 1 nanometer to about 500 micrometers;
c. lyophilizing the decellularized cartilage (DCC) tissue fragments; and
d. cryogrinding the DCC tissue fragments to produce DCC tissue powder,
wherein the DCC tissue powder has no more than about 20% of dsDNA left, has about 85% or more glycosaminoglycan content retained, in comparison to fresh cartilage tissue without decellularization, and wherein the DCC tissue powder stimulates bone marrow stem cell responses.

### Claim 16 (depends on 6)

A method of preparing the hyaline cartilage tissue paste of claim 6, the method comprising:
a. solubilizing decellularized cartilage tissue powder having particulates ranging in size from between about 1 nanometers and about 500 micrometers in an acidic solvent to make a solubilized decellularized cartilage (SDCC) solution;
b. incubating the SDCC solution with a protease;
c. separating the supernatant containing solubilized particulates and solids containing slightly solubilized particulates by centrifuging the SDCC solution and collecting the solids; and
d. mixing between about 10% to about 90% w/v of methacrylated hyalurionic acid (MeHA) to between about 10% to about 90% of the solids containing slightly solubilized particulates to form a paste,
wherein the paste has a yield stress up to about 400 Pa.

### Claim 17 (depends on 16)

The method of claim 16, wherein the step of incubating the SDCC solution further comprises the step of adjusting the pH of the SDCC solution at the end of incubation to physiological pH.

### Claim 18 (depends on 16)

The method of claim 16, further comprising the step of crosslinking the paste to form a hyaline cartilage tissue gel.

### Claim 19 (depends on 18)

The method of claim 18, wherein said crosslinking is accomplished through exposure to UV light.

### Claim 20

A method of preparing hyaline cartilage tissue gel, the method comprising:
a. solubilizing decellularized cartilage tissue powder having particulates ranging in size from between about 1 nanometers and about 500 micrometers to form a solubilized decellularized cartilage (SDCC) solution;
b. incubating the SDCC solution with a protease;
c. separating a supernatant portion containing solubilized particulates from a portion of solids containing slightly solubilized particulates by centrifuging the SDCC solution and collecting the solids;
d. mixing between about 10% to about 90% w/v of methacrylated hyalurionic acid (MeHA) to between about 10% to about 90% of the solids containing slightly solubilized particulates; and
e. molding the mixture in a three dimensional shape and crosslinking the mixture to form a hyaline cartilage tissue gel,
wherein the hyaline cartilage tissue gel has mechanical compression, fluid-induced shear stress, and hydrostatic pressure resembling physiological conditions of cartilage tissue.

### Claim 21 (depends on 20)

The method of claim 20, wherein said crosslinking is accomplished using UV light.

### Claim 22 (depends on 4)

A method of preparing the hyaline cartilage tissue hydrogel of claim 4, the method comprising:
a. solubilizing decellularized cartilage tissue powder to make a solubilized decellularized cartilage (SDCC) solution;
b. incubating the SDCC solution with a protease;
c. separating a supernatant portion containing solubilized particulates and solids containing slightly solubilized particulates by centrifuging the SDCC solution and collecting the supernatant;
d. methacrylating the solubilized particulates in the supernatant by mixing the supernatant with glycidyl methacrylate, triethylamine, and tetrabutyl ammonium bromide to make a MeSDCC solution;
e. obtaining dry methacrylated SDCC powder by precipitating the MeSDCC solution and subsequently lyophilizing said solution;
f. mixing the dry methacrylated SDCC powder with a solution that facilitates crosslinking to form a methacrylated SDCC solution, and
g. crosslinking said methacrylated SDCC solution to form a hyaline cartilage tissue hydrogel,
wherein the DCC tissue powder includes particulates ranging in size from between about 1 nanometers and about 500 micrometers; and
wherein the hyaline cartilage tissue hydrogel has mechanical compression, fluid-induced shear stress, and hydrostatic pressure resembling physiological condition of cartilage tissue.

### Claim 23 (depends on 22)

The method of claim 22, wherein said solution that facilitates crosslinking is a photoinitiator solution and the crosslinking is done via exposure to UV light.

### Claim 24 (depends on 22)

The method of claim 22, further comprising the step of transferring said methacrylated SDCC solution to a three dimensional mold prior to crosslinking.

### Claim 25 (depends on 10)

A method for coating microspheres with decellularized cartilage (DCC) powder to form the composition of claim 10, the method comprising:
a. solubilizing decellularized cartilage tissue powder to make a solubilized decellularized cartilage (SDCC) solution;
b. suspending microspheres in solution for lyophilization;
c. assembling scaffolds by flowing said microsphere suspension into a three dimensional mold;
d. contacting the scaffolds with the SDCC solution for a time sufficient for the decellularized cartilage powder to attach to the microspheres forming the scaffolds; and
e. removing the scaffolds for lyophilization;
wherein the DCC tissue powder includes particulates ranging in size from between about 1 nanometers and about 500 micrometers.

### Claim 26

A method for encapsulating decellularized cartilage powder in a pore-containing polymer, the method comprising:
a. solubilizing decellularized cartilage tissue powder to make a solubilized decellularized cartilage (SDCC) solution;
b. providing an encapsulating solution containing the SDCC and pore-containing polymer, wherein the pore-containing polymer is insoluble in the encapsulating solution;
c. fabricating microspheres encapsulating decellularized cartilage tissue powder; wherein the DCC tissue powder includes particulates ranging in size from between about 1 nanometers and about 500 micrometers.

### Claim 27 (depends on 1)

A method of treating an osteochondral defect, the method comprising: contacting an osteochondral defect with the composition of claim 1 comprising the decellularized cartilage (DCC) powder, wherein the DCC powder includes particulates ranging in size from between about 1 nanometers and about 500 micrometers.

### Claim 28 (depends on 27)

The method of claim 27, wherein said osteochondral defect is selected from the group consisting of joint disorders in knees, ankle, elbow, patella, vertebrae, femoral head, glenoid of the scapula, jaw, and growth plates.

### Claim 29 (depends on 27)

The method of claim 27, wherein said composition is selected from the group consisting of decellularized cartilage (DCC) powder paste, putty, hydrogel, and scaffolds.

### Claim 30 (depends on 1)

A method of treating a full and partial thickness cartilage defect, the method comprising: contacting said defect with the composition of claim 1 comprising the decellularized cartilage (DCC) powder, wherein the DCC tissue powder includes particulates ranging in size from between about 1 nanometers and about 500 micrometers.

### Claim 31 (depends on 30)

The method of claim 30, wherein said composition is selected from the group consisting of decellularized cartilage (DCC) powder paste, putty, hydrogel, and scaffolds.

### Claim 32 (depends on 30)

The method of claim 30, wherein said full and partial thickness cartilage defect is selected from the group consisting of knee, elbow, wrist, ankle, shoulder, jaw, and hip joint cartilage defects.
